(Q33417013)

26 July 2017

title

Real-world study of everolimus in advanced progressive neuroendocrine tumors (English)

1 reference

26 July 2017

Francesco Panzuto

1

0 references

Sara Pusceddu

Sara Pusceddu

22

0 references

Marialuisa Appetecchia

Marialuisa Appetecchia

28

0 references

Maria Rosaria Ambrosio

Maria Rosaria Ambrosio

24

0 references

Davide Campana

Davide Campana

26

0 references

Giacomo Cartenì

Giacomo Cartenì

27

0 references

Maria Chiara Zatelli

Maria Chiara Zatelli

6

0 references

Nicola Fazio

Nicola Fazio

3

0 references

Massimo Falconi

Massimo Falconi

31

0 references

Filippo de Braud

Filippo de Braud

4

0 references

Stefano Cascinu

Stefano Cascinu

16

0 references

Annamaria Colao

30

Annamaria Colao

1 reference

26 July 2017

29

Alfredo Berruti

1 reference

26 July 2017

Maria Rinzivillo

2

1 reference

26 July 2017

Gabriele Luppi

5

1 reference

26 July 2017

Francesca Lugli

7

1 reference

26 July 2017

Paola Tomassetti

8

1 reference

26 July 2017

Ferdinando Riccardi

9

1 reference

26 July 2017

Carmen Nuzzo

10

1 reference

26 July 2017

Maria Pia Brizzi

11

1 reference

26 July 2017

Antongiulio Faggiano

12

1 reference

26 July 2017

Alberto Zaniboni

13

1 reference

26 July 2017

Elisabetta Nobili

14

1 reference

26 July 2017

Davide Pastorelli

15

1 reference

26 July 2017

Marco Merlano

17

1 reference

26 July 2017

Silvana Chiara

18

1 reference

26 July 2017

Lorenzo Antonuzzo

19

1 reference

26 July 2017

Chiara Funaioli

20

1 reference

26 July 2017

Francesca Spada

21

1 reference

26 July 2017

Annalisa Fontana

23

1 reference

26 July 2017

Alessandra Cassano

25

1 reference

26 July 2017

Gianfranco Delle Fave

32

1 reference

26 July 2017

publication date

12 August 2014

1 reference

26 July 2017

1 reference

26 July 2017

volume

19

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

966-974

1 reference

Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Epidemiology of gastroenteropancreatic neuroendocrine tumours.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Everolimus for advanced pancreatic neuroendocrine tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

The randomized registry trial--the next disruptive technology in clinical research?

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4153458

Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25117065

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25117065

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Promising advances in the treatment of malignant pancreatic endocrine tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25117065

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1634/THEONCOLOGIST.2014-0037

1 reference

26 July 2017

1 reference

26 July 2017

1 reference